Progress after Adult Stem Cell Therapy Offers New Hope to Iowa Spinal Cord Injury Patient

Rich Welsh, a 28 year-old insurance agent from Klemme, Iowa who suffered a spinal cord injury after an automobile accident in 1999, is now on the road to recovery after stem cell therapy in Cologne, Germany.

Cologne, Germany (PRWEB) February 7, 2008 -- Rich Welsh, a 28 year-old insurance agent from Klemme, Iowa who suffered a spinal cord injury after an automobile accident in 1999, is now on the road to recovery after stem cell therapy in Cologne, Germany.

-------------------------------------------------------------------------

Mr. Welsh became a C-5 quadriplegic after his unfortunate accident. Since then, he has received adult stem cell therapy twice; the latest time in mid-2007. Following these treatments, Mr. Welsh can now feel hot and cold sensations in his stomach and his muscle spasms have decreased significantly. He has also regained the ability to sweat. However, his most notable gain has occurred since his second treatment - return of sexual function. "Since that treatment I have started regaining my sexual function. No more blue pill," joked Welsh. When asked what advice he would give to those considering this treatment, Mr. Welsh replied, "If you happen to come across the chance of having autologous stem cell therapy that may improve your quality of life - do not let it pass you by."
---------------------------------------------------------------------------------------

Since that treatment I have started regaining my sexual function. No more blue pill

The spinal cord injury treatment at XCell-Center employs (autologous) stem cells that come from the patient's own bone marrow. After the stem cells are separated from the bone marrow, they are implanted into the spinal canal under local anesthesia. This procedure is very safe and takes about 30 minutes.

About the XCell-Center
The XCell-Center is the first privately-owned center in Europe to specialize in regenerative medicine using autologous bone marrow adult stem cell therapy. Newly completed in early 2007, the XCell-Center is a fully licensed clinic featuring the latest medical equipment and technology. Its specialized medical team of German physicians includes: neurologists, endocrinologists, cardiologists, radiologists, hematologists, and pharmacologists. The XCell-Center works in accordance with German law and European guidelines.

The XCell-Center currently treats Diabetes and its complications (Erectile Dysfunction and Peripheral Artery Disease), Stroke, Spinal Cord Injuries, Ischemic Heart Disease and degenerative diseases such as Multiple Sclerosis, Parkinson's and Alzheimer's.

The XCell-Center has submitted its SCIDIM I and II trials to its investigational review board. In these trials, diabetes (type I and II) patients are being treated with their own stem cells and compared with a control group receiving traditional therapy. The findings will be presented at different international scientific meetings. Also later this year, another clinical trial for stroke patients will commence. These trials are only open to German residents.

--------------------------------------------------------------------------------------------------
For more information on Stem Cell Therapy:
XCell-Center Website: http://www.xcell-center.com

XCell-Center GmbH
at the Institute for Regenerative Medicine
Custodisstrasse 3-17
Cologne, Germany 50679

Phone: 1-866-680-8202 (USA Toll-Free)
(+49) 0221-802-5095 (Germany)

Fax: (+49) 0221-2921-2550 (Germany)
1-713-583-9322 (USA)

###

http://www.prweb.com/releases/2008/2/prweb680883.htm

Sunshine vitamin' may help prevent cancer
New Kerala Thu, 07 Feb 2008 10:28 AM PST
Washington, Feb 7 : A researcher at Dalhousie University has claimed that a vitamin D pill could block the development of some cancers, strengthen bones, prevent multiple sclerosis and alleviate winter depression.

More Brain Research Suggests "Use It Or Lose It", Australia
Queensland Brain Institute (QBI) scientists have found another important clue to why nerve cells die in neurodegenerative diseases, based on studies of the developing brain.

Biogen Rests Rumors
Motley Fool - USA
No discussion of a Biogen earnings call would be complete without a mention of its multiple sclerosis treatment Tysabri. Tysabri worldwide sales by Biogen ...
See all stories on this topic

Globe promotes Hall to VP of human resources
Boston Globe - United States
(Jenn Abelson) Two multiple sclerosis patients developed skin cancer after taking Tysabri, a drug from Biogen Idec Inc. and Elan Corp. that suppresses the ...
See all stories on this topic

Ahead of the Bell: Biogen Idec
Forbes - NY,USA
Biogen late Wednesday posted quarterly profit and sales far above analyst estimates, driven by growing revenue from multiple sclerosis drugs Tysabri and ...
See all stories on this topic

Letter In Medical Journal Suggests MS Drug, Melanoma Linked
CNNMoney.com - USA
PLC's (ELN) MS drug Tysabri. The letter says the cases suggest that the drug may lead to development and progression of the skin cancer in high-risk ...
See all stories on this topic

Multiple Sclerosis Drug May Cause Skin Cancer
MedIndia - Chennai,India
Tysabri is a monoclonal antibody that helps treat autoimmune disorders such as Multiple Sclerosis and Crohn's disease. It has proved effective in slowing ...
See all stories on this topic

Stocks to Watch - BIIB, NICE, PEX, PTVL
TransWorldNews (press release) - Monroe,GA,USA
Global in-market net sales in 2007 of TYSABRI were $343 million, comprised of $218 million in the US and $125 million in Europe. On a reported basis, ...
See all stories on this topic

Stocks to Watch - BIIB, NICE, PEX, PTVL
TransWorldNews (press release) - Monroe,GA,USA
Global in-market net sales in 2007 of TYSABRI were $343 million, comprised of $218 million in the US and $125 million in Europe. On a reported basis, ...
See all stories on this topic

Sheldon Brown dies
Bicycling - USA
Doctors, at first stumped, eventually diagnosed him with primary-progressive multiple sclerosis in August 2007. Brown is survived by his wife, Harriet, ...
See all stories on this topic

Acorda Therapeutics To Sell 2.66 Mln Common Shares In Public ...
RTT News - Williamsville,NY,USA
The Company intends to use the net proceeds from this offering to complete its second Phase 3 Fampridine-SR clinical trial in multiple sclerosis and to ...
See all stories on this topic